Serum Neurofilament Light Levels in Natalizumab-Treated Patients With MS Who Switch to Extended-Interval Dosing From Every-4-Week Dosing
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice
Mult. Scler. 2022 Nov 15;[EPub Ahead of Print], J Foley, K Xiong, T Hoyt, CM Singh, E Riddle, C de Moor, T Plavina, N CampbellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.